Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology.

IF 4.6 2区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Molecular Therapy-Methods & Clinical Development Pub Date : 2024-11-05 eCollection Date: 2024-12-12 DOI:10.1016/j.omtm.2024.101368

Jakub Gubala, Valentin Mieville, Daniel Benamran, Jean-Christophe Tille, Massimo Valerio, Patrycja Nowak-Sliwinska

引用次数: 0

Abstract

Despite significant advancements in targeted- and immunotherapies, millions of patients with cancer still succumb to the disease each year. In renal cell carcinoma, up to 25% of metastatic patients do not respond to first-line therapies. This reality underscores the urgent need for innovative or repurposed therapies to effectively treat these patients. Patient-derived organoids represent a promising model for evaluating treatment efficacy and toxicity, offering a potential breakthrough in personalized medicine. However, utilizing organoid models for drug screening presents several challenges. Our protocol aims to address these obstacles by outlining a practical approach to successfully isolate and cultivate patient-derived renal cell carcinoma and kidney organoids for treatment screening purposes.

查看原文本刊更多论文

从患者来源的材料中生成和维持肾脏和肾癌类器官，用于药物开发和精确肿瘤学。

尽管靶向和免疫疗法取得了重大进展，但每年仍有数百万癌症患者死于这种疾病。在肾细胞癌中，高达25%的转移性患者对一线治疗无效。这一现实强调了迫切需要创新或重新利用疗法来有效治疗这些患者。患者来源的类器官代表了评估治疗疗效和毒性的有前途的模型，为个性化医疗提供了潜在的突破。然而，利用类器官模型进行药物筛选存在一些挑战。我们的方案旨在通过概述一种实用的方法来成功地分离和培养用于治疗筛选目的的患者源性肾细胞癌和肾类器官，从而解决这些障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Therapy-Methods & Clinical Development Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

9.90

自引率

4.30%

发文量

163

审稿时长

12 weeks

期刊介绍： The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Topics of particular interest within the journal''s scope include: Gene vector engineering and production, Methods for targeted genome editing and engineering, Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells, Methods for gene and cell vector delivery, Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine, Analysis of gene and cell vector biodistribution and tracking, Pharmacology/toxicology studies of new and next-generation vectors, Methods for cell isolation, engineering, culture, expansion, and transplantation, Cell processing, storage, and banking for therapeutic application, Preclinical and QC/QA assay development, Translational and clinical scale-up and Good Manufacturing procedures and process development, Clinical protocol development, Computational and bioinformatic methods for analysis, modeling, or visualization of biological data, Negotiating the regulatory approval process and obtaining such approval for clinical trials.